Forgot your password?

Enter the email address for your account and we'll send you a verification to reset your password.

Your email address
Your new password
Psilocybin is an effective prodrug compound produced by many species of mushrooms together, and is now used for the treatment of depression and post-traumatic stress disorder, and have reached heights in recent years.
The psychoactive substance, psilocybin, is of course commonly dismissed as merely a recreational drug but has recently fetched enough clinical credence for state and local governments to the extent of considering it legal for medical purposes.

According to Rolling Stone, even the federal government is agreeing to the use of “magic mushrooms” in therapy. At the tail-end of 2018, British mental health treatment company Compass Pathways announced that the FDA officially allowed them a “breakthrough therapy designation” in which the company with due permission begin trials using psilocybin. This is going to be a breakthrough in the drug’s checkered legal history.

“It really does represent a significant development in the whole history of psychedelic research,” said UCLA psychiatry and behavioral sciences professor Charles Grob, who held trials of his own involving the main ingredient in magic mushrooms during the mid-2000s.

While researchers initiated to study the drug earnestly in the year 1990s and have demanded long back for approval to clinically investigate its effects, the first real approval or rather sign of approval that the government has started taking this effort seriously came in August 2017.
That’s when the FDA granted MDMA the same “breakthrough designation” for post-traumatic stress complications that Compass Pathways fetched a year later. It’s believed that this move served as signs of yielding, of sorts, on behalf of the government that the good side of these anxiety-alleviating drugs was simply too obvious to keep ignoring.
As a pioneer and the pivotal person of these efforts, Rick Doblin of the Multidisciplinary Association of Psychedelic Studies (MAPS), has since predicted that both MDMA and psilocybin would be federally legal by 2021. To his point, should Compass Pathways succeed in its trials, the FDA is ready to approve psilocybin for the kind of patients that simply do not seek any relief from traditional anti-depressants.

For more interesting stories download the Lopscoop application from Google Play Store and earn extra money by sharing it on social media.
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0

Add you Response

  • Please add your comment.